Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures

Journal of Medical Virology - Tập 92 Số 6 - Trang 568-576 - 2020
Yixuan Wang1, Yuyi Wang1, Yan Chen2, Qingsong Qin1
1Laboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong, China
2Department of Pediatric, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Tóm tắt

Abstract

By 27 February 2020, the outbreak of coronavirus disease 2019 (COVID‐19) caused 82 623 confirmed cases and 2858 deaths globally, more than severe acute respiratory syndrome (SARS) (8273 cases, 775 deaths) and Middle East respiratory syndrome (MERS) (1139 cases, 431 deaths) caused in 2003 and 2013, respectively. COVID‐19 has spread to 46 countries internationally. Total fatality rate of COVID‐19 is estimated at 3.46% by far based on published data from the Chinese Center for Disease Control and Prevention (China CDC). Average incubation period of COVID‐19 is around 6.4 days, ranges from 0 to 24 days. The basic reproductive number (R0) of COVID‐19 ranges from 2 to 3.5 at the early phase regardless of different prediction models, which is higher than SARS and MERS. A study from China CDC showed majority of patients (80.9%) were considered asymptomatic or mild pneumonia but released large amounts of viruses at the early phase of infection, which posed enormous challenges for containing the spread of COVID‐19. Nosocomial transmission was another severe problem. A total of 3019 health workers were infected by 12 February 2020, which accounted for 3.83% of total number of infections, and extremely burdened the health system, especially in Wuhan. Limited epidemiological and clinical data suggest that the disease spectrum of COVID‐19 may differ from SARS or MERS. We summarize latest literatures on genetic, epidemiological, and clinical features of COVID‐19 in comparison to SARS and MERS and emphasize special measures on diagnosis and potential interventions. This review will improve our understanding of the unique features of COVID‐19 and enhance our control measures in the future.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMoa2001017

10.1038/s41586-020-2012-7

10.1038/s41586-020-2008-3

10.1080/22221751.2020.1725399

10.1097/CM9.0000000000000722

10.1016/S0140-6736(20)30154-9

Gorbalenya AE, 2020, Severe acute respiratory syndrome‐related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group, bioRxiv

10.1002/jmv.25681

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID‐19) in China, Zhonghua Liu Xing Bing Xue Za Zhi, 41, 145

10.1038/nrd.2015.37

10.1016/S0140-6736(20)30251-8

10.1002/jmv.25731

10.1016/j.meegid.2020.104260

Wrapp D, 2020, Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation, bioRxiv

Lam TT‐Y, 2020, Identification of 2019‐nCoV related coronaviruses in Malayan pangolins in southern China, bioRxiv

10.1002/jmv.25682

10.1056/NEJMoa2001316

10.2807/1560-7917.ES.2020.25.4.2000058

10.1016/S0140-6736(20)30260-9

10.1093/jtm/taaa021

10.1002/jmv.25723

10.2807/1560-7917.ES.2020.25.5.2000062

10.1001/jama.2020.1585

Respiratory Care Committee of Chinese Thoracic Society, 2020, Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia, Zhonghua Jie He He Hu Xi Za Zhi, 17, E020

10.3201/eid2605.200198

Bai SL, 2020, Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province, Zhonghua Yu Fang Yi Xue Za Zhi, 54, E005

10.1093/jtm/taaa030

10.1016/S0140-6736(20)30360-3

10.1016/j.ajog.2020.02.017

10.1056/NEJMoa2002032

10.1056/NEJMoa2001191

10.1056/NEJMc2001899

10.1056/NEJMc2001737

National Health Commission of China. The guidelines for diagnosis and treatment of novel coronavirus (2019‐nCoV) infected pneumonia (the sixth edition draft) issued by the National Health Commission of China.http://www.gov.cn/zhengce/zhengceku/2020‐02/19/content_5480948.htm2020. Accessed February 2020.

10.1016/S0140-6736(20)30211-7

10.1016/S0140-6736(20)30183-5

Fan C, 2020, ACE2 expression in kidney and testis may cause kidney and testis damage after 2019‐nCoV infection, medRxiv

Chai X, 2020, Specific ACE2 expression in cholangiocytes may cause liver damage after 2019‐nCoV infection, bioRxiv

10.1046/j.1440-1843.2003.00520.x

10.1007/s00330-020-06731-x

10.1148/radiol.2020200432

Wang M, 2020, Clinical diagnosis of 8274 samples with 2019‐novel coronavirus in Wuhan, medRxiv

10.1093/clinchem/hvaa029

10.1002/jmv.25702

10.1001/jama.2020.2783

10.1128/JCM.42.5.2351-2352.2004

Zhou G, 2020, A model simulation study on effects of intervention measures in Wuhan COVID‐19 epidemic, med Rxiv

10.2807/1560-7917.ES.2020.25.6.2000094

Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus (2019‐nCoV) infected pneumonia (first edition draft).

10.3346/jkms.2020.35.e79

10.1038/s41422-020-0282-0

10.1136/thorax.2003.012658

10.1186/1743-422X-2-69

10.1126/scitranslmed.aal3653

10.1038/nature17180

10.1126/sciadv.aav4580

Li XY, 2020, The keypoints in treatment of the critical coronavirus disease 2019 patient, Zhonghua Jie He He Hu Xi Za Zhi, 43, E026

10.1001/jama.2020.2565

10.1016/j.antiviral.2016.11.006

10.4161/hv.27464

10.1016/j.micinf.2020.01.003

Chen Q, 2020, Mental health care for medical staff in China during the COVID‐19 outbreak, Lancet, 7

10.1016/j.micinf.2020.01.004

10.1016/j.ijid.2020.01.050

10.1016/j.idc.2019.07.001

10.1155/2016/7247983

10.1016/j.ccm.2016.11.007

10.1038/nrmicro.2016.81

10.3390/v11100940

10.1371/journal.ppat.1004457

10.1038/sdata.2014.33

10.1080/01652176.2020.1727993

Guan W‐J, 2020, Clinical characteristics of 2019 novel coronavirus infection in China, medRxiv

10.1016/S0140-6736(03)13077-2

10.1016/j.gastro.2003.08.001

GENG QS, 2003, Guidelines for the prevention and treatment of SARS, Dongguan Sci Technol J, 5, 7

10.1002/hep.20111

Du HWQ, 2004, Analysis of SARS inpatients in Beijing in 2003, Chin Gen Pract, 7, 231

10.1016/S1473-3099(13)70204-4

10.26719/2013.19.supp1.S12

10.1056/NEJMoa1306742

PLoS Curr 2013 5 State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS‐COV) in humans

10.1016/S0140-6736(13)60982-4

10.1056/NEJMoa1303729

National Health and Family Planning Commission of People's Republicao of China, 2015, Diagnosis and treatment plan for Middle East respiratory syndrome cases (2015 edition), Virologica Sinica, 352354

10.1186/s12879-017-2576-5

World Health Organization.WHO MERS global summary and assessment of risk.https://www.who.int/csr/disease/coronavirus_infections/risk‐assessment‐august‐2018.pdf. Accessed July 2019.

10.1136/bmj.326.7403.1358

10.1056/NEJMoa1211721

10.1016/S1473-3099(13)70154-3

10.1007/s40265-017-0830-1

10.1042/CS20050188

Thông tin
Thông tin xuất bản

Journal of Medical Virology

Tập 92 Số 6

568-576

Thông tin tác giả